New Implications of the Mosunetuzumab Data & What it Means for Patients with DLBCL

Although regimens in the last decade have proven curative for most patients with diffuse large B-cell lymphoma (DLBCL), a considerable proportion require additional treatment. Novel therapies have constantly been introduced in the treatment landscape of DLBCL.

It is debatable as to whether these regimens remain “the” standard of care, or if they have now become “a” standard of care.

Mosunetuzumab is a T-cell engaging bispecific IgG antibody currently being developed for multiple types of lymphatic cancers.

Updated results for two trials were presented at the the American Society of Hematology (ASH): a phase I/II trial evaluating mosunetuzumab monotherapy in previously untreated older/unfit patients with DLBCL; and a subgroup analysis of a phase Ib/II trial evaluating mosunetuzumab in combination with polatuzumab in patients with relapsed/refractory DLBCL.

Excited by the results presented at ASH, the NoeticInsight team rapidly gathered expert opinions on the future of the DLBCL. Through our virtual blinded platform, we easily connected with leaders in the field of lymphatic cancers who were able to share their honest and robust opinions.